U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Pharmacoeconomic Review Report: Migalastat (Galafold): (Amicus Therapeutics): Indication: Fabry Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Feb.

Cover of Pharmacoeconomic Review Report: Migalastat (Galafold)

Pharmacoeconomic Review Report: Migalastat (Galafold): (Amicus Therapeutics): Indication: Fabry Disease [Internet].

Show details

Appendix 2Summary of Key Outcomes

Table 5When Considering Only Costs, Outcomes & Quality of Life, How Attractive Is Migalastat Relative to Agalsidase alfa?

Migalastat vs. Agalsidase alfaAttractiveSlightly AttractiveEqually AttractiveSlightly UnattractiveUnattractiveNA
Costs (total)
Drug treatment costs alone
Clinical outcomes
Quality of life
ICER or net benefit calculationCDR revised base case: the ICUR for migalastat vs. agalsidase alfa ranges from $200,487 per QALY to $55,935,921 per QALY. CDR noted that there is a substantial uncertainty around the efficacy equivalence and the disutility value assumptions.

CDR = CADTH Common Drug Review; ICER = incremental cost-effectiveness ratio; ICUR = incremental cost-utility ratio; QALY = quality-adjusted life-year; vs. = versus.

Table 6When Considering Only Costs, Outcomes & Quality of Life, How Attractive Is Migalastat Relative to Agalsidase beta?

Migalastat vs. Agalsidase betaAttractiveSlightly AttractiveEqually AttractiveSlightly UnattractiveUnattractiveNA
Costs (total)
Drug treatment costs alone
Clinical outcomes
Quality of life
ICER or net benefit calculationCDR revised base case: migalastat is dominant compared with agalsidase beta. CDR noted that there is a substantial uncertainty around the efficacy equivalence and the disutility value assumptions.

CDR = CADTH Common Drug Review; ICER = incremental cost-effectiveness ratio; vs. = versus.

Copyright © 2018 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK533453

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (855K)

Other titles in this collection

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...